Status:
COMPLETED
Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers
Lead Sponsor:
Biotec Pharmacon ASA
Conditions:
Diabetes
Diabetic Ulcer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Evaluation of efficacy and safety of SBG vs placebo in the treatment of chronic diabetic foot ulcers.
Detailed Description
The objective of this study is to evaluate efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) on chronic diabetic foot ulcers.
Eligibility Criteria
Inclusion
- Patients with chronic diabetic foot ulcer
Exclusion
- Insufficient nutritional status, renal function or diabetes control
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT00804414
Start Date
October 1 2008
End Date
September 1 2009
Last Update
January 26 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidad Complutense de Madrid
Madrid, Spain, 28040